Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use
Declarations
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Julia Paik is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable
Additional information about this Adis Drug Review can be found here
Abstract
Diroximel fumarate (Vumerity®), an
orally administered disease-modifying drug (DMD), expands the available treatment
options for adults with relapsing forms of multiple sclerosis (MS), including
clinically isolated syndrome, relapsing-remitting MS (RRMS), and active
secondary progressive MS. It demonstrates bioequivalence to dimethyl fumarate
and was developed to provide similar clinical benefits, but with an improved
gastrointestinal (GI) tolerability profile. In RRMS patients who are
treatment-naïve or were previously treated with interferon-β or glatiramer
acetate, diroximel fumarate reduces annualized relapse rates, with most
patients experiencing no relapses during treatment, and reduces the formation
of new MS-associated brain lesions. Diroximel fumarate has an acceptable
tolerability profile that is consistent with that of dimethyl fumarate, albeit
with a significantly lower rate of GI adverse events.
© Springer Nature Switzerland AG 2021
